Metsera Q2 net loss $68.7M; cash $530.9M; key Ph2 data for MET-097i/MET-233i expected Sept 2025

Metsera, Inc.

2025-Q2 EPS reported -$1.62

Net loss of $68.7M for Q2 2025 vs $26.7M Q2 2024; R&D expenses rose to $60.5M from $20.9M.
Cash $530.9M as of June 30, 2025; runway into 2027.
MET-097i VESPER-1 and interim VESPER-3 data expected Sept 2025; Phase 3 start late 2025.
MET-233i showed 8.4% weight loss at 5 weeks, 19-day half-life; 12-week data due late 2025.
Oral GLP-1 lead candidate four-week data expected late 2025; co-administration data for MET-233i+097i by early 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.